ArticleFrontiers in medicine2025
Comparing the longer regimen and the shorter regimen for multidrug-resistant pulmonary tuberculosis patients treated under the programmatic management of drug-resistant tuberculosis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant tuberculosis is a major public health concern with prolonged infectivity, a complex treatment regimen, and lower treatment success rates. Despite the significant progress made by India in the control of Tuberculosis, it remains the second leading cause of mortality among infectious diseases. Shorter treatment courses for multidrug-resistant tuberculosis (MDR-TB) can enhance patient adherence by decreasing the length of time for medication intake and alleviating the challenges associated with prolonged treatment. Evaluating the effectiveness of various treatment regimens is crucial for identifying the best balance among treatment duration, efficacy, adverse drug effects, and patient adherence. A prospective, observational study on 50 MDR-TB patients was carried out at a tertiary care hospital. The final cure rates were 88% in the shorter regimen and 84% in the longer regimen, with 12% treatment failure in both groups. Both shorter and longer regimens demonstrated comparable efficacy with slightly better adherence in the shorter regimen. Clinical trial registration: The study was registered in the Clinical Trials Registry-India (Indian Council of Medical Research-National Institute of Medical Statistics), https://ctri.nic.in/, CTRI registration number CTRI/2024/01/061453, registration date 15/1/2024, date of first enrollment is 24/1/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.